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ABSTRACT 
 
Introduction: Fluorescence-guided surgery could potentially reduce local recurrence after pancreatic cancer resection. 
However, the ideal contrast agent for this purpose is not yet determined. The monoclonal antibody cetuximab targets the 
EGFR receptor, which is overexpressed in 64% of pancreatic cancers. We investigated the efficacy of near-infrared 
emitting silver sulphide Quantum Dot (QD)-cetuximab nanoconjugates for targeting EGFR-positive pancreatic cancer. 
 
Methods: 2-Mercaptopropionic acid-coated QDs were prepared from AgNO3 and Na2S. Pancreatic cancer cell lines 
PANC-1 and CFPAC-1 were confirmed EGFR-positive using a commercial AlexaFluor488-cetuximab probe. Non-
conjugated QD and cetuximab-conjugated QD (QD-cetuximab) toxicity was assessed after 24 and 48 hours using MTT 
assay. Fluorescence microscopy was performed following a) formaldehyde-fixed immunofluorescence and b) live staining 
with QD-cetuximab for four hours at concentrations corresponding to 0, 10, 50, 100, 200, 400 and 600µg ml-1 of silver.  
 
Results: Untargeted QDs were non-toxic in both cell lines after 48 hours at all investigated concentrations, whereas QD-
cetuximab was toxic at 100µg ml-1 after 24 hours in PANC-1 and at 10µg ml-1 in CFPAC-1. Fixed immunofluorescence 
demonstrated EGFR targeting by QD-cetuximab at concentrations of 50µg ml-1 upwards in both cell lines. Live staining 
demonstrated similar efficacy of EGFR targeting up to 50µg ml-1, although a reduction of fluorescence at higher 
concentrations was observed when compared to fixed immunofluorescence.  
 
Conclusion: Silver sulphide QD-cetuximab nanoconjugates have the potential to target live EGFR-positive pancreatic 
cancer cells at doses of up to 50 µg ml-1. The reduction in QD fluorescence observed at higher concentrations is likely to 
be secondary to cetuximab toxicity.  
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1. INTRODUCTION 
 
Pancreatic cancer 
Pancreatic cancer has been increasing in incidence over the last three decades and is now the 11th most common cancer in 
the UK1. Unfortunately, due to aggressive tumor biology and the late onset of symptoms, most patients (60%) are diagnosed 
with stage 3 or 4 disease2. As a result, only 10% of patients will undergo curative-intent surgery and only 28% will receive 
chemotherapy2,3. Whilst complete surgical resection can cure the disease, recurrence is common with palliative treatments 
only providing a modest survival benefit4,5.  
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Fluorescence-guided surgery 
Fluorescence-guided surgery (FGS) is an emerging field that aims to assist the surgeon in the intraoperative identification  
of tumor to aid resection. Presently, surgeons rely on visual inspection and palpation of tissues to determine the location 
and extent of the tumor, with preoperative information usually provided by non-invasive imaging such as Computerized 
Tomography (CT) and Magnetic Resonance Imaging (MRI). Intraoperative imaging techniques (such as liver ultrasound 
to identify hepatic metastases) are only helpful at the beginning of the procedure as the tissue planes become distorted once 
resection begins. In addition, the rise of laparoscopic surgery has removed the tactile element of surgery, making the visual 
identification of residual tumor the most significant (and often only) intraoperative real time diagnostic tool. Research 
efforts have focused on finding ways to enhance the intraoperative visual detection of tumor to aid resection. 
 
Quantum dots 
Quantum dots (QDs) are nanometer-sized crystals of inorganic semiconductors with physical properties that are not present 
in the bulk form of the same material6,7. Some of their unique optical properties include8: 
 
a) High quantum yield (ratio of the number of  photons absorbed to the number of photons emitted through 
fluorescence)9; 
b) Size and composition-tuneable light emission in the visible or near infrared (NIR) range; 
c) A broad excitation window that allows a single light source to excite multiple QDs of varying emission bands at 
the same time (multiplexing)10; and 
d) Chemical stability and photostability. 
 
The typical structure of QDs for biomedical applications includes a core (with or without a shell) and a hydrophilic coating 
with or without a biomolecule of interest to functionalize the QD, such as antibodies specific to membrane-bound tumor 
biomarkers. These nanoconjugates can be used as contrast agents during FGS, potentially increasing the likelihood of 
complete tumor resection and reducing postoperative recurrence rates. Although human tissue is usually autofluorescent 
in the visible light range, it shows little NIR fluorescence. QDs emitting in the NIR I range (700-1000nm) show better 
promise as contrast agents in FGS as they allow for deeper tissue imaging whilst minimising interference from normal 
surrounding tissue. 
 
Silver sulphide QD–cetuximab nanoconjugates 
Our collaborators at the University of Koç developed a non-toxic silver sulphide QD11 coated with 2-mercaptopropionic 
acid (2-MPA) with or without cetuximab (Figure 1). Cetuximab is a monoclonal antibody targeting the human EGFR 
receptor, which is overexpressed in 64% of pancreatic cancers12. The nanoconjugates have a diameter of ~12nm and a peak 
emission at 800nm. 
 
Aim 
Our aim was to investigate the efficacy of NIR-emitting QDs and QD-cetuximab nanoconjugates in the targeting of EGFR-
positive pancreatic cancer. 
 
Figure 1 Diagrammatic representation of 2-MPA-coated silver sulphide quantum dots with or without cetuximab conjugation* 
 
*single conjugation shown for clarity 
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2. METHODS 
 
Cell culture 
PANC-1 was purchased from RIKEN BioResource Centre (RIKEN BRC, Tsukuba, Japan) and CFPAC-1 from ECACC 
(European Collection of Authenticated Cell Cultures, Salisbury, United Kingdom). PANC-1 was cultured in Dulbecco’s 
modified Eagle’s medium containing 4.5g L-1 glucose and 0.58 g L-1 L-glutamine (Lonza®) supplemented with 10% Fetal 
Bovine Serum (FBS) (Gibco™). CFPAC-1 was cultured in Iscove’s modified Dulbecco’s medium containing 4.5g L-1 
glucose, 4.0mM L-glutamine and HEPES buffer (Gibco™) supplemented with 10% FBS. 
 
QD-cetuximab nanoconjugate synthesis 
2-MPA-coated silver sulphide QDs were synthesized from 2-MPA, AgNO3 and Na2S using previously described 
methods11. Cetuximab was conjugated using thiolene chemistry and a heterofunctional PEG linker. Unbound cetuximab 
was removed by washing with Phosphate Buffered Saline (PBS) using a 100kDa centrifugal filter. 
 
Cell imaging 
PANC-1 and CFPAC-1 were confirmed EGFR-positive by fluorescence microscopy using a commercial AlexaFluor488-
cetuximab probe (abcam®). To demonstrate that the synthesized QD-cetuximab nanoconjugates had a similar binding 
efficacy to the commercial probe, direct immunofluorescence of fixed cells was performed as follows: 24 hours post-
seeding, cells were washed three times in PBS and fixed using 4% formaldehyde at room temperature. After 20 minutes, 
formaldehyde was removed, cells washed three times with PBS and PBS with 10% FBS added (to prevent non-specific 
nanoconjugate binding). After 30 minutes, the PBS with 10% FBS was aspirated and the cells then incubated at 37.0ºC 
with increasing concentrations of QD-cetuximab (corresponding to 0, 10, 50, 100, 200, 400 and 600µg ml-1 of silver) for 
one hour. Lastly, cells were washed three times with PBS and fluorescence microscopy performed using an Olympus® 
BX63 fluorescence microscope. To assess the EGFR targeting efficacy of QD-cetuximab in living cells, live targeting was 
performed as follows: 20 hours post-seeding, cells were washed three times in PBS and then incubated at 37.0ºC with the 
aforementioned increasing concentrations of QD-cetuximab. After 4 hours, cells were washed three times with PBS, fixed 
with 4% formaldehyde at room temperature for 20 minutes and washed three times with PBS before having fluorescence 
microscopy performed as per fixed immunofluorescence. 
 
Evaluation of cytotoxicity 
The effect of QD and QD-cetuximab on cell metabolic activity was assessed using Methyl Thiazolyl Tetrazolium (MTT) 
assay. Cells were seeded on day 1, QD or QD-cetuximab in increasing concentrations (0, 10, 50, 100, 200, 400, 600µg   
ml-1) were added either on day 2 (48 hour exposure) or day 3 (24 hour exposure) and MTT assay performed on day 4. 
Readings were taken using absorbance detection at 570nm on an Infinite® 200 PRO plate reader (Tecan®). 
 
 
3. Results 
 
Fixed immunofluorescence studies 
The commercial probe confirmed overexpression of EGFR in both CFPAC-1 and PANC-1 (data not shown). Fixed 
immunofluorescence showed increasing NIR fluorescence with increasing doses of QD-cetuximab from 50µg ml-1 up to 
the maximum investigated dose of 600µg ml-1, demonstrating good binding efficacy (Figure 2). 
 
Live immunofluorescence studies 
Whilst targeting efficacy was comparable until 50-100µg ml-1 in CFPAC-1 and 50µg ml-1 in PANC-1, higher doses resulted 
in a loss of near-infrared fluorescence (Figure 3).  
 
Metabolic activity studies 
Non-functionalized QDs (i.e. without cetuximab) showed no evidence of cellular toxicity after 24 or 48 hours incubation 
(one-way ANOVA 48 hours CFPAC-1 p=0.088, PANC-1 p=0.704). However, QD-cetuximab was shown to be toxic in 
CFPAC-1 at 24 and 48 hours from 10 µg ml-1 and in PANC-1 at 24 hours from 100 µg ml-1 and at 48 hours from 10 µg 
ml-1 (one way ANOVA p<0.001 for both cell lines at both time points). 
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Figure 2 Fixed immunofluorescence of CFPAC-1 and PANC-1 using QD-cetuximab nanoconjugates* 
 
*BF = bright field, NIR = near infrared, Comp = composite 
 
Figure 3 Live immunofluorescence of CFPAC-1 and PANC-1 using QD-cetuximab nanoconjugates* 
 
*BF = bright field, NIR = near infrared, Comp = composite 
 
 
4. Conclusion 
 
Non-functionalized QDs do not show evidence of cellular toxicity in two pancreatic cancer cell lines at doses of up to 
600µg ml-1. QD-cetuximab nanoconjugates have the potential to target EGFR-positive pancreatic cancer cells at doses of 
up to 50µg ml-1, but show reduced targeting efficacy when compared to fixed immunofluorescence at the same 
concentrations. Given the MTT assay results, and the fact that cetuximab is known to cause antibody-dependent cellular 
cytotoxicity in a number of tumor cell lines13, the observed reduction in QD fluorescence at higher concentrations is likely 
to be secondary to cetuximab toxicity. For effective tissue-targeting in FGS using QD-antibody nanoconjugates, the 
optimal dose of antibody needs to be determined that allows for effective tumor targeting whilst minimising antibody-
induced cytotoxicity. Future research should also focus on discovery of membrane-bound biomarkers in pancreatic cancer 
that do not cause cellular toxicity when bound to as potential targets for functionalized quantum dots.  
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